\-\ Texto\\:\\ \ \(0\)\
\-\ pe\\ was\\ remarkable\\ for\\ enlarged\\,\\ painless\\,\\ smooth\\ thyroid\\ gland\\ without\\ palpable\\ nodules\\ and\\ normal\\ dtrs\\.\\ \\ patient\\ had\\ mildly\\ coarse\\ facial\\ features\\ \\(including\\ brow\\,\\ jaw\\,\\ and\\ nose\\)\\.\\ \\ no\\ visual\\ field\\ defects\\.\\ remainder\\ of\\ physical\\ exam\\ normal\\.\ \(0\)\
\-\ serum\\ ft4\\,\\ total\\ t3\\,\\ and\\ tsh\\ concentrations\\ were\\ all\\ elevated\\:\ \(0\)\
\-\ free\\ t4\\ \\:\\ 3\\.1\\	total\\ t3\\ \\:\\ 427\\	tsh\\ \\:\\ 5\\.58\\	\ \(0\)\
\-\ hgh\\ \\:\\ 1\\.3\\ \\	igf\\-1\\ \\:\\ 362\\	alpha\\ subunit\\ \\:\\ 3\\.6\\	\ \(0\)\
\-\ oral\\ glucose\\ tolerance\\ test\\ failed\\ to\\ suppress\\ gh\\ suggesting\\ unregulated\\ secretion\\ of\\ gh\\.\\ \ \(0\)\
\-\ acth\\,\\ prolactin\\,\\ fsh\\,\\ and\\ lh\\ all\\ within\\ normal\\ limits\ \(0\)\
\-\ surgical\\ resection\\ is\\ the\\ treatment\\ of\\ choice\\ for\\ pituitary\\ adenomas\\,\\ however\\,\\ somatostatin\\ analogs\\ can\\ be\\ used\\ to\\ effectively\\ reduce\\ autonomous\\ secretion\\ of\\ pituitary\\ hormones\\,\\ as\\ well\\ decrease\\ the\\ size\\ of\\ the\\ adenomas\\ by\\ approximately\\ 50\\%\\.\\ \\ due\\ to\\ the\\ invasive\\ nature\\ of\\ this\\ macroadenoma\\,\\ octreotide\\ therapy\\ was\\ initiated\\ in\\ this\\ patient\\ to\\ facilitate\\ a\\ more\\ optimal\\ surgical\\ outcome\\.\ \(0\)\
\-\ mri\\ examination\\ of\\ the\\ sella\\ revealed\\ a\\ 2\\.6x1\\.5cm\\ enhancing\\ intrasellar\\ mass\\ encasing\\ the\\ left\\ internal\\ carotid\\ artery\\ and\\ expanding\\ the\\ posterior\\ sella\\ wall\\.\\ \\ in\\-111\\-octreotide\\ scan\\ showed\\ increase\\ uptake\\ in\\ the\\ intrasellar\\ mass\\.\\ \\ \ \(0\)\
\-\ note\\:\\ an\\ increased\\ uptake\\ of\\ octreotide\\,\\ a\\ somatostatin\\ analog\\ that\\ is\\ a\\ marker\\ of\\ neuroendocrine\\ neoplasms\\,\\ was\\ also\\ noted\\ in\\ the\\ thyroid\\ gland\\.\\ \\ this\\ was\\ due\\ to\\ a\\ coincident\\ papillary\\ thyroid\\ carcinoma\\.\ \(0\)\
\-\ pituitary\\ macroadenoma\\ secreting\\ tsh\\ and\\ gh\ \(0\)\
\-\ \\â\\€\\¢\\ pituitary\\ macroadenoma\\ \ \(0\)\
\-\ \\â\\€\\¢\\ craniopharyngioma\\ \ \(0\)\
\-\ \\â\\€\\¢\\ meningioma\\ \ \(0\)\
\-\ \\â\\€\\¢\\ aneurysm\\ \ \(0\)\
\-\ \\â\\€\\¢\\ rathke\\ cleft\\ cyst\ \(0\)\
\-\ \\â\\€\\¢\\ metastatic\\ disease\ \(13\)\
\-\ 55\\-year\\-old\\ caucasian\\ female\\ presents\\ with\\ 3\\-week\\ history\\ of\\ left\\ neck\\ mass\\.\\ \\ also\\ reports\\ 20lb\\ weight\\ loss\\ over\\ 3\\-month\\ period\\ and\\ onset\\ of\\ new\\ headache\\ over\\ prior\\ 3\\ weeks\\ associated\\ with\\ nausea\\,\\ emesis\\,\\ and\\ olfactory\\ hypersensitivity\\.\\ \\ no\\ visual\\ changes\\ were\\ noted\\.\ \(0\)\
\-\ tsh\\-secreting\\ adenomas\\ represent\\ a\\ small\\ percentage\\ of\\ pituitary\\ adenomas\\,\\ and\\ those\\ that\\ co\\-secrete\\ gh\\ are\\ even\\ more\\ rare\\,\\ with\\ fewer\\ than\\ 55\\ reported\\ in\\ the\\ medical\\ literature\\.\\ \\ the\\ elevated\\ thyroid\\ hormone\\ and\\ growth\\ hormone\\ levels\\ were\\ likely\\ contributing\\ to\\ the\\ patient\\â\\€\\™s\\ weight\\ loss\\,\\ coarse\\ facial\\ features\\,\\ and\\ thyroid\\ goiter\\,\\ and\\ the\\ patient\\â\\€\\™s\\ headaches\\ were\\ due\\ to\\ mass\\ effect\\ from\\ the\\ compression\\ of\\ the\\ optic\\ chiasm\\.\\ \\ \ \(0\)\
\-\ while\\ surgical\\ resection\\ remains\\ the\\ treatment\\ of\\ choice\\ for\\ pituitary\\ adenomas\\,\\ studies\\ have\\ demonstrated\\ that\\ somatostatin\\ analogs\\ can\\ effectively\\ reduce\\ autonomous\\ secretion\\ of\\ pituitary\\ hormones\\,\\ as\\ well\\ decrease\\ the\\ size\\ of\\ the\\ adenomas\\ by\\ approximately\\ 50\\%\\.\\ \\ due\\ to\\ the\\ invasive\\ nature\\ of\\ this\\ macroadenoma\\,\\ as\\ evidenced\\ by\\ the\\ encasement\\ of\\ the\\ left\\ internal\\ carotid\\ artery\\,\\ the\\ neoplasm\\ was\\ not\\ resectable\\ at\\ this\\ time\\.\\ \\ \\ therefore\\,\\ the\\ patient\\ was\\ started\\ on\\ octreotide\\ therapy\\ in\\ order\\ to\\ shrink\\ the\\ size\\ of\\ the\\ neoplasm\\ and\\ facilitate\\ a\\ more\\ optimal\\ surgical\\ outcome\\.\ \(0\)\
\-\ references\\:\ \(0\)\
\-\ abs\\ r\\,\\ et\\ la\\.\\ autonomously\\ functioning\\ thyroid\\ nodules\\ in\\ a\\ patient\\ with\\ a\\ thyrotropin\\-secreting\\ pituitary\\ adenoma\\:\\ possible\\ cause\\-\\-effect\\ relationship\\.\\ eur\\ j\\ endocrinol\\.\\ 1994\\ oct\\;131\\(4\\)\\:355\\-8\\.\\	\ \(0\)\
\-\ chanson\\ p\\,\\ et\\ al\\.\\ diagnosis\\ and\\ treatment\\ of\\ pituitary\\ adenomas\\.\\ minerva\\ endocrinol\\.\\ 2004\\ dec\\;29\\(4\\)\\:241\\-75\\	\ \(0\)\
\-\ grainger\\,\\ r\\.\\ g\\.\\,\\ allison\\,\\ d\\.\\,\\ adam\\,\\ a\\.\\,\\ \\&\\ dixon\\,\\ a\\.\\ k\\.\\ \\(eds\\.\\)\\.\\ \\(2008\\)\\.\\ grainger\\ and\\ allison\\'s\\ diagnostic\\ radiology\\:\\ a\\ textbook\\ of\\ medical\\ imaging\\ \\(5th\\ ed\\.\\)\\.\ \(0\)\
\-\ sen\\ o\\,\\ et\\ al\\.\\ silent\\ pituitary\\ macroadenoma\\ co\\-secreting\\ growth\\ hormone\\ and\\ thyroid\\ stimulating\\ hormone\\.\\ j\\ clin\\ neurosci\\.\\ 2005\\ apr\\;12\\(3\\)\\:318\\-20\\.\ \(0\)\
\-\ skoric\\ t\\,\\ et\\ al\\.\\ clinical\\ and\\ morphological\\ features\\ of\\ undifferentiated\\ monomorphous\\ gh\\/tsh\\-secreting\\ pituitary\\ adenoma\\.\\ eur\\ j\\ endocrinol\\.\\ 1999\\ jun\\;140\\(6\\)\\:528\\-37\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ pituitary\\:\\ 0\\.33165355968838095\ \(0\)\
\-\ adenomas\\:\\ 0\\.26623701746935635\ \(0\)\
\-\ gh\\:\\ 0\\.22547052761543013\ \(0\)\
\-\ secreting\\:\\ 0\\.20363502154720572\ \(0\)\
\-\ macroadenoma\\:\\ 0\\.18899973768095324\ \(0\)\
\-\ thyroid\\:\\ 0\\.17981263963357458\ \(0\)\
\-\ octreotide\\:\\ 0\\.17220135990335048\ \(0\)\
\-\ the\\:\\ 0\\.1630525039887344\ \(0\)\
\-\ tsh\\:\\ 0\\.15790878951429793\ \(0\)\
\-\ endocrinol\\:\\ 0\\.1498474959131773\ \(0\)\
\-\ somatostatin\\:\\ 0\\.1410663255934258\ \(0\)\
\-\ of\\:\\ 0\\.14072439010037227\ \(0\)\
\-\ hormone\\:\\ 0\\.1331281872360512\ \(0\)\
\-\ secretion\\:\\ 0\\.12464093823834377\ \(0\)\
\-\ and\\:\\ 0\\.11482178441036332\ \(0\)\
\-\ et\\:\\ 0\\.10242028700451852\ \(0\)\
\-\ grainger\\:\\ 0\\.09989833060878488\ \(0\)\
\-\ allison\\:\\ 0\\.09989833060878488\ \(0\)\
\-\ analogs\\:\\ 0\\.09404421706228387\ \(0\)\
\-\ autonomous\\:\\ 0\\.09018821104617206\ \(0\)\
\-\ effectively\\:\\ 0\\.08730812216538329\ \(0\)\
\-\ hormones\\:\\ 0\\.08730812216538329\ \(0\)\
\-\ facilitate\\:\\ 0\\.08610067995167524\ \(0\)\
\-\ intrasellar\\:\\ 0\\.08610067995167524\ \(0\)\
\-\ eur\\:\\ 0\\.08500841560792817\ \(0\)\
\-\ optimal\\:\\ 0\\.0814540086188823\ \(0\)\
\-\ features\\:\\ 0\\.07890142688006654\ \(0\)\
\-\ al\\:\\ 0\\.07791373134802895\ \(0\)\
\-\ due\\:\\ 0\\.07515477847639475\ \(0\)\
\-\ to\\:\\ 0\\.07354358510882687\ \(0\)\
\-\ t3\\:\\ 0\\.07080143209536321\ \(0\)\
\-\ outcome\\:\\ 0\\.06965446549216184\ \(0\)\
\-\ coarse\\:\\ 0\\.06886380017548072\ \(0\)\
\-\ was\\:\\ 0\\.0683489837679654\ \(0\)\
\-\ sella\\:\\ 0\\.06765635796177265\ \(0\)\
\-\ were\\:\\ 0\\.06739536166368794\ \(0\)\
\-\ reduce\\:\\ 0\\.0665640936180256\ \(0\)\
\-\ size\\:\\ 0\\.06639564841801679\ \(0\)\
\-\ patient\\:\\ 0\\.06378726456115381\ \(0\)\
\-\ surgical\\:\\ 0\\.06354642170782396\ \(0\)\
\-\ choice\\:\\ 0\\.061987088770878364\ \(0\)\
\-\ invasive\\:\\ 0\\.059485880730470335\ \(0\)\
\-\ nature\\:\\ 0\\.057719298278466155\ \(0\)\
\-\ in\\:\\ 0\\.056919025127405175\ \(0\)\
\-\ decrease\\:\\ 0\\.05618901495265464\ \(0\)\
\-\ 55\\:\\ 0\\.05618901495265464\ \(0\)\
\-\ this\\:\\ 0\\.05615799736675306\ \(0\)\
\-\ visual\\:\\ 0\\.05577524793131054\ \(0\)\
\-\ carotid\\:\\ 0\\.05506614951837108\ \(0\)\
\-\ facial\\:\\ 0\\.05390463963708012\ \(0\)\
\-\ growth\\:\\ 0\\.05390463963708012\ \(0\)\
\-\ more\\:\\ 0\\.05384481541050933\ \(0\)\
\-\ total\\:\\ 0\\.0535645523191687\ \(0\)\
\-\ gland\\:\\ 0\\.05310477311428722\ \(0\)\
\-\ brow\\:\\ 0\\.0522725009707889\ \(0\)\
\-\ hgh\\:\\ 0\\.0522725009707889\ \(0\)\
\-\ autonomously\\:\\ 0\\.0522725009707889\ \(0\)\
\-\ chanson\\:\\ 0\\.0522725009707889\ \(0\)\
\-\ sen\\:\\ 0\\.0522725009707889\ \(0\)\
\-\ skoric\\:\\ 0\\.0522725009707889\ \(0\)\
\-\ adenoma\\:\\ 0\\.05211834935288183\ \(0\)\
\-\ nodules\\:\\ 0\\.051942487565352635\ \(0\)\
\-\ uptake\\:\\ 0\\.050267686541353\ \(0\)\
\-\ unregulated\\:\\ 0\\.04994916530439244\ \(0\)\
\-\ 20lb\\:\\ 0\\.04994916530439244\ \(0\)\
\-\ minerva\\:\\ 0\\.04994916530439244\ \(0\)\
\-\ mass\\:\\ 0\\.04994116795135962\ \(0\)\
\-\ 427\\:\\ 0\\.04830073241548458\ \(0\)\
\-\ 362\\:\\ 0\\.04830073241548458\ \(0\)\
\-\ analog\\:\\ 0\\.04830073241548458\ \(0\)\
\-\ coincident\\:\\ 0\\.04830073241548458\ \(0\)\
\-\ dixon\\:\\ 0\\.04830073241548458\ \(0\)\
\-\ neurosci\\:\\ 0\\.04830073241548458\ \(0\)\
\-\ morphological\\:\\ 0\\.04830073241548458\ \(0\)\
\-\ monomorphous\\:\\ 0\\.04830073241548458\ \(0\)\
\-\ subunit\\:\\ 0\\.047022108531141936\ \(0\)\
\-\ treatment\\:\\ 0\\.046710649594738\ \(0\)\
\-\ abs\\:\\ 0\\.045977396749088115\ \(0\)\
\-\ effect\\:\\ 0\\.04585801246162064\ \(0\)\
\-\ 50\\:\\ 0\\.04565457336312963\ \(0\)\
\-\ weight\\:\\ 0\\.045587555034143246\ \(0\)\
\-\ fsh\\:\\ 0\\.04509410552308603\ \(0\)\
\-\ adam\\:\\ 0\\.04509410552308603\ \(0\)\
\-\ neoplasm\\:\\ 0\\.0446266487508785\ \(0\)\
\-\ elevated\\:\\ 0\\.04456536463907714\ \(0\)\
\-\ lh\\:\\ 0\\.044328963860180266\ \(0\)\
\-\ shrink\\:\\ 0\\.044328963860180266\ \(0\)\
\-\ internal\\:\\ 0\\.044057271708331736\ \(0\)\
\-\ concentrations\\:\\ 0\\.04305033997583762\ \(0\)\
\-\ suppress\\:\\ 0\\.04305033997583762\ \(0\)\
\-\ fewer\\:\\ 0\\.04305033997583762\ \(0\)\
\-\ la\\:\\ 0\\.04305033997583762\ \(0\)\
\-\ jun\\:\\ 0\\.04305033997583762\ \(0\)\
\-\ that\\:\\ 0\\.0425538782721704\ \(0\)\
\-\ acth\\:\\ 0\\.042504207803964085\ \(0\)\
\-\ neuroendocrine\\:\\ 0\\.042504207803964085\ \(0\)\
\-\ resectable\\:\\ 0\\.042504207803964085\ \(0\)\
\-\ tolerance\\:\\ 0\\.0420056281937838\ \(0\)\
\-\ encasing\\:\\ 0\\.0420056281937838\ \(0\)\
\-\ silent\\:\\ 0\\.0420056281937838\ \(0\)\
\-\ stimulating\\:\\ 0\\.0420056281937838\ \(0\)\
\-\ resection\\:\\ 0\\.04190468015696437\ \(0\)\
\-\ approximately\\:\\ 0\\.04171247268970388\ \(0\)\
\-\ by\\:\\ 0\\.04164148928378216\ \(0\)\
\-\ undifferentiated\\:\\ 0\\.04154697941278126\ \(0\)\
\-\ medical\\:\\ 0\\.04154689558615748\ \(0\)\
\-\ dtrs\\:\\ 0\\.041122336967781704\ \(0\)\
\-\ olfactory\\:\\ 0\\.041122336967781704\ \(0\)\
\-\ encasement\\:\\ 0\\.04072700430944115\ \(0\)\
\-\ eds\\:\\ 0\\.04072700430944115\ \(0\)\
\-\ artery\\:\\ 0\\.04060073125423816\ \(0\)\
\-\ prolactin\\:\\ 0\\.04035719530487595\ \(0\)\
\-\ normal\\:\\ 0\\.040036784803800574\ \(0\)\
\-\ apr\\:\\ 0\\.04000981314224028\ \(0\)\
\-\ loss\\:\\ 0\\.039827377272565745\ \(0\)\
\-\ as\\:\\ 0\\.039393733828479556\ \(0\)\
\-\ percentage\\:\\ 0\\.039372484602985924\ \(0\)\
\-\ all\\:\\ 0\\.038914744926011456\ \(0\)\
\-\ evidenced\\:\\ 0\\.038799001301385236\ \(0\)\
\-\ contributing\\:\\ 0\\.03827772839105508\ \(0\)\
\-\ textbook\\:\\ 0\\.03827772839105508\ \(0\)\
\-\ ft4\\:\\ 0\\.03803385963847948\ \(0\)\
\-\ hypersensitivity\\:\\ 0\\.03779994753619065\ \(0\)\
\-\ oct\\:\\ 0\\.03779994753619065\ \(0\)\
\-\ dec\\:\\ 0\\.037575210857476934\ \(0\)\
\-\ therapy\\:\\ 0\\.03756079241908139\ \(0\)\
\-\ expanding\\:\\ 0\\.03715056841247739\ \(0\)\
\-\ marker\\:\\ 0\\.03715056841247739\ \(0\)\
\-\ 1994\\:\\ 0\\.03715056841247739\ \(0\)\
\-\ goiter\\:\\ 0\\.03675523575413683\ \(0\)\
\-\ over\\:\\ 0\\.03635003372391577\ \(0\)\
\-\ functioning\\:\\ 0\\.0362091035822633\ \(0\)\
\-\ jaw\\:\\ 0\\.036038044586935956\ \(0\)\
\-\ 140\\:\\ 0\\.03587194452813473\ \(0\)\
\-\ initiated\\:\\ 0\\.03571052397208301\ \(0\)\
\-\ rathke\\:\\ 0\\.03571052397208301\ \(0\)\
\-\ chiasm\\:\\ 0\\.034692401800611325\ \(0\)\
\-\ relationship\\:\\ 0\\.034692401800611325\ \(0\)\
\-\ noted\\:\\ 0\\.03466045112438465\ \(0\)\
\-\ 131\\:\\ 0\\.034560670693355444\ \(0\)\
\-\ alpha\\:\\ 0\\.03443190008774036\ \(0\)\
\-\ clin\\:\\ 0\\.034305959835750764\ \(0\)\
\-\ can\\:\\ 0\\.03430546384366719\ \(0\)\
\-\ left\\:\\ 0\\.033450023978943824\ \(0\)\
\-\ 2008\\:\\ 0\\.033387188305686544\ \(0\)\
\-\ emesis\\:\\ 0\\.033178799857173064\ \(0\)\
\-\ nose\\:\\ 0\\.03307738038128514\ \(0\)\
\-\ failed\\:\\ 0\\.032977724812075226\ \(0\)\
\-\ 1999\\:\\ 0\\.03287977284055835\ \(0\)\
\-\ t4\\:\\ 0\\.03278346719883251\ \(0\)\
\-\ remarkable\\:\\ 0\\.032237335026958976\ \(0\)\
\-\ literature\\:\\ 0\\.031900175972830416\ \(0\)\
\-\ well\\:\\ 0\\.03165372999827193\ \(0\)\
\-\ glucose\\:\\ 0\\.03158175790285959\ \(0\)\
\-\ craniopharyngioma\\:\\ 0\\.03158175790285959\ \(0\)\
\-\ remains\\:\\ 0\\.031135034309924658\ \(0\)\
\-\ 2005\\:\\ 0\\.031063852639290075\ \(0\)\
\-\ 2004\\:\\ 0\\.03078765214728899\ \(0\)\
\-\ also\\:\\ 0\\.030749392472714885\ \(0\)\
\-\ field\\:\\ 0\\.030720633245307008\ \(0\)\
\-\ neoplasms\\:\\ 0\\.030460131532436045\ \(0\)\
\-\ papillary\\:\\ 0\\.030460131532436045\ \(0\)\
\-\ 5th\\:\\ 0\\.030396815409774056\ \(0\)\
\-\ painless\\:\\ 0\\.03027224418199317\ \(0\)\
\-\ order\\:\\ 0\\.030210959632051736\ \(0\)\
\-\ for\\:\\ 0\\.029720895153777384\ \(0\)\
\-\ cleft\\:\\ 0\\.029522526622070368\ \(0\)\
\-\ suggesting\\:\\ 0\\.02946872293288298\ \(0\)\
\-\ serum\\:\\ 0\\.029310278253708476\ \(0\)\
\-\ caucasian\\:\\ 0\\.029055567396103793\ \(0\)\
\-\ therefore\\:\\ 0\\.02881169864352819\ \(0\)\
\-\ remainder\\:\\ 0\\.028764146081834942\ \(0\)\
\-\ period\\:\\ 0\\.028577786541239356\ \(0\)\
\-\ 29\\:\\ 0\\.02848683144423472\ \(0\)\
\-\ defects\\:\\ 0\\.028179398670457295\ \(0\)\
\-\ optic\\:\\ 0\\.028136795866039573\ \(0\)\
\-\ those\\:\\ 0\\.027969483226385598\ \(0\)\
\-\ started\\:\\ 0\\.02753307475918554\ \(0\)\
\-\ even\\:\\ 0\\.02749500119187612\ \(0\)\
\-\ represent\\:\\ 0\\.027199190955673896\ \(0\)\
\-\ pe\\:\\ 0\\.02702177583013486\ \(0\)\
\-\ smooth\\:\\ 0\\.02698694258731201\ \(0\)\
\-\ test\\:\\ 0\\.02658466861885756\ \(0\)\
\-\ mildly\\:\\ 0\\.026393649237290907\ \(0\)\
\-\ increase\\:\\ 0\\.02623919107674742\ \(0\)\
\-\ oral\\:\\ 0\\.02617855505273032\ \(0\)\
\-\ radiology\\:\\ 0\\.02617855505273032\ \(0\)\
\-\ ed\\:\\ 0\\.026148475976844377\ \(0\)\
\-\ references\\:\\ 0\\.026059174676440915\ \(0\)\
\-\ levels\\:\\ 0\\.02591336398955518\ \(0\)\
\-\ limits\\:\\ 0\\.02582762596902918\ \(0\)\
\-\ with\\:\\ 0\\.025601540525440815\ \(0\)\
\-\ free\\:\\ 0\\.025443651195077906\ \(0\)\
\-\ reports\\:\\ 0\\.025417184400686757\ \(0\)\
\-\ nausea\\:\\ 0\\.02510876642190728\ \(0\)\
\-\ diagnostic\\:\\ 0\\.024912007149249887\ \(0\)\
\-\ aneurysm\\:\\ 0\\.024887880583928757\ \(0\)\
\-\ rare\\:\\ 0\\.02467519448967396\ \(0\)\
\-\ note\\:\\ 0\\.024606017985935036\ \(0\)\
\-\ meningioma\\:\\ 0\\.0244925479255882\ \(0\)\
\-\ used\\:\\ 0\\.024470121083658675\ \(0\)\
\-\ headaches\\:\\ 0\\.024381281307221333\ \(0\)\
\-\ studies\\:\\ 0\\.023977139960292382\ \(0\)\
\-\ compression\\:\\ 0\\.02393621085199993\ \(0\)\
\-\ reported\\:\\ 0\\.023542237797604126\ \(0\)\
\-\ including\\:\\ 0\\.023391932765500376\ \(0\)\
\-\ palpable\\:\\ 0\\.022963318014762334\ \(0\)\
\-\ new\\:\\ 0\\.02261290006355324\ \(0\)\
\-\ headache\\:\\ 0\\.02253253337730168\ \(0\)\
\-\ 12\\:\\ 0\\.02234413117436749\ \(0\)\
\-\ enlarged\\:\\ 0\\.02228268231953857\ \(0\)\
\-\ cause\\:\\ 0\\.0222674225214431\ \(0\)\
\-\ possible\\:\\ 0\\.022146785417262203\ \(0\)\
\-\ showed\\:\\ 0\\.02177138339048789\ \(0\)\
\-\ revealed\\:\\ 0\\.02143222815072747\ \(0\)\
\-\ no\\:\\ 0\\.021258422182847386\ \(0\)\
\-\ while\\:\\ 0\\.021124500477137917\ \(0\)\
\-\ onset\\:\\ 0\\.020988798637100452\ \(0\)\
\-\ examination\\:\\ 0\\.020916112028624437\ \(0\)\
\-\ clinical\\:\\ 0\\.0207150369835266\ \(0\)\
\-\ enhancing\\:\\ 0\\.020476013120728345\ \(0\)\
\-\ demonstrated\\:\\ 0\\.020088117258757185\ \(0\)\
\-\ neck\\:\\ 0\\.01999511168729936\ \(0\)\
\-\ wall\\:\\ 0\\.01988345083102953\ \(0\)\
\-\ changes\\:\\ 0\\.01975423345524555\ \(0\)\
\-\ weeks\\:\\ 0\\.0195895376485769\ \(0\)\
\-\ carcinoma\\:\\ 0\\.019551464081267483\ \(0\)\
\-\ likely\\:\\ 0\\.019532521747328394\ \(0\)\
\-\ scan\\:\\ 0\\.019392415725952718\ \(0\)\
\-\ time\\:\\ 0\\.019373991109440734\ \(0\)\
\-\ however\\:\\ 0\\.01934646479166176\ \(0\)\
\-\ cyst\\:\\ 0\\.018855518126260497\ \(0\)\
\-\ than\\:\\ 0\\.01852893112457431\ \(0\)\
\-\ prior\\:\\ 0\\.01828803927957192\ \(0\)\
\-\ metastatic\\:\\ 0\\.017926797509293886\ \(0\)\
\-\ is\\:\\ 0\\.017902727721082232\ \(0\)\
\-\ physical\\:\\ 0\\.017723259303431514\ \(0\)\
\-\ increased\\:\\ 0\\.017675193886079264\ \(0\)\
\-\ without\\:\\ 0\\.017240791515711586\ \(0\)\
\-\ associated\\:\\ 0\\.01722812841487101\ \(0\)\
\-\ imaging\\:\\ 0\\.0171777540174837\ \(0\)\
\-\ diagnosis\\:\\ 0\\.016944343473320116\ \(0\)\
\-\ posterior\\:\\ 0\\.016902364891442187\ \(0\)\
\-\ small\\:\\ 0\\.016860691611042776\ \(0\)\
\-\ mri\\:\\ 0\\.016778243414518897\ \(0\)\
\-\ exam\\:\\ 0\\.01645429707513875\ \(0\)\
\-\ have\\:\\ 0\\.01632859707181476\ \(0\)\
\-\ had\\:\\ 0\\.016285513780138507\ \(0\)\
\-\ female\\:\\ 0\\.015772644759065868\ \(0\)\
\-\ presents\\:\\ 0\\.01572379492528234\ \(0\)\
\-\ within\\:\\ 0\\.015054299386845826\ \(0\)\
\-\ disease\\:\\ 0\\.013720545304066894\ \(0\)\
\-\ be\\:\\ 0\\.01325952301217161\ \(0\)\
\-\ from\\:\\ 0\\.012981610479622565\ \(0\)\
\-\ not\\:\\ 0\\.012903771602006333\ \(0\)\
\-\ an\\:\\ 0\\.01249912935461828\ \(0\)\
\-\ history\\:\\ 0\\.012488056789243751\ \(0\)\
\-\ are\\:\\ 0\\.01240296225544732\ \(0\)\
\-\ at\\:\\ 0\\.012346027286548137\ \(0\)\
\-\ on\\:\\ 0\\.009871822035254168\ \(0\)\
